Ultrasound-Assisted Gene Transfer of Anti-Biofilm Peptides to the Salivary Gland
超声辅助将抗生物膜肽基因转移至唾液腺
基本信息
- 批准号:8041732
- 负责人:
- 金额:$ 11.39万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-03-01 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvantAlternative TherapiesAnimalsArchitectureAreaBacteriaBiological FactorsBone TissueCell membraneCellsChronicDebridementDentalDental HygieneDietDoseEquilibriumEvaluationExcisionFrequenciesGenderGene DeliveryGene TransferGene Transfer TechniquesGenesGoalsHabitsHealedHealthHost DefenseHumanIn VitroIndividualInflammationMedical DeviceMedicineMethodsMicrobial BiofilmsMicrobubblesModelingMusNon-Human GeneNon-Viral VectorOral cavityOral healthPathologyPatientsPeptidesPeriodontal DiseasesPeriodontiumPhysiologic pulsePhysiologicalProcessProductionPropertyProteinsPseudomonas aeruginosaPublic HealthReactionRelative (related person)ReportingResearchRodent ModelSalivaSalivarySalivary GlandsStreptococcus mutansStructureTechniquesTechnologyTestingTherapeuticTimeTissuesTooth LossToothbrushingUltrasonographyViral Vectorantimicrobialbaseconventional therapydesigngene therapyhealingimmunogenicitymicrobialmicrobicidemicroorganismnon-viral gene therapyoral bacteriaoral biofilmpathogenpre-clinicalresearch studysaliva secretionsalivary assaysoft tissuetherapeutic targettherapeutic transgenetoothbrushtransgene expression
项目摘要
DESCRIPTION (provided by applicant): The present proposal will optimize and apply a method for non-viral gene transfer to the salivary glands. This method utilizes low frequency ultrasound pulses to destroy microbubbles, causing local cavitation and opening transient pores in cell membranes enabling non-viral vectors to enter cells of the salivary gland. This proposed method is derived from existing ultrasound-assisted gene transfer (UAGT) techniques that our group has recently shown is capable of robust, stable, and long-lasting gene transfer to the salivary glands. UAGT has several important advantages over other gene transfer methods, in particular a presumed lack of immunogenicity and therefore the theoretical option to re-dose. Gene transfer to the salivary glands presents the opportunity to achieve endogenous production and salivary secretion of peptide therapeutics. Endogenous production overcomes many of the challenges that have thus far limited the utility of emerging anti-biofilm peptide molecules for targeting individual bad actors in the periodontal flora. Chief among these limitations are manufacturing, stability and delivery of the therapeutics itself, as well as the challenge of achieving a steady-state, sustained concentration of the therapeutic in the saliva. The long-term goal of this research therefore is to lay the pre-clinical groundwork for UAGT to the salivary glands for application in dental medicine. In order to achieve this goal, we will first apply what is already known regarding UAGT to the salivary gland and undertake a careful histopathological evaluation of the effect of this technique on salivary gland architecture and viability. Secondly, we will endeavor an initial proof-of-principle study wherein we will introduce genes with known anti-biofilm activity in model microorganisms (S. mutans and P. aeruginosa) to the salivary glands and assay in vitro the biofilm-inhibiting properties of saliva produced by treated animals. Once this technology has been proven to be reliable, safe and effective in the rodent model, we speculate that it may be an attractive adjuvant or even a primary approach to dealing with destructive microbial pathogens in the periodontium, particularly in vulnerable patients physically incapable of routine oral hygiene.
PUBLIC HEALTH RELEVANCE: In this application, we propose to use a non-viral gene therapy approach to address the public health issue of chronic periodontal inflammation and tissue destruction by a subset of oral flora. Specifically, we propose a method of inhibiting biofilm formation, a natural process that is accelerated in the most vulnerable to of dental patients who are unable to maintain routine oral hygiene (i.e. tooth brushing). The immediate application of this technology to public health is to provide a gene therapy-based treatment that may bridge vulnerable patients between episodic periodontal treatments.
描述(由申请人提供):本提案将优化并应用非病毒基因转移至唾液腺的方法。该方法利用低频超声脉冲破坏微泡,引起局部空化并打开细胞膜中的瞬时孔,使非病毒载体能够进入唾液腺细胞。该方法源自现有的超声辅助基因转移(UAGT)技术,我们的研究小组最近已经证明该技术能够将强大,稳定和持久的基因转移到唾液腺。与其他基因转移方法相比,UAGT具有几个重要的优势,特别是假定缺乏免疫原性,因此理论上可以选择重新给药。向唾液腺的基因转移提供了实现肽治疗剂的内源性产生和唾液分泌的机会。内源性产生克服了许多挑战,这些挑战迄今为止限制了新兴的抗生物膜肽分子用于靶向牙周植物群中的个体不良作用物的效用。这些限制中主要的是治疗剂本身的制造、稳定性和递送,以及在唾液中实现治疗剂的稳态、持续浓度的挑战。因此,本研究的长期目标是为唾液腺UAGT在牙科医学中的应用奠定临床前基础。为了实现这一目标,我们将首先应用什么是已经知道的关于UAGT的唾液腺,并进行仔细的组织病理学评估的影响,这种技术对唾液腺的结构和活力。其次,我们将奋进初步的原理验证研究,其中我们将在模型微生物中引入具有已知抗生物膜活性的基因(S。变形杆菌和铜绿假单胞菌)对唾液腺的作用,并在体外测定由处理的动物产生的唾液的生物膜抑制特性。一旦这项技术在啮齿动物模型中被证明是可靠、安全和有效的,我们推测它可能是一种有吸引力的辅助剂,甚至是处理牙周组织中破坏性微生物病原体的主要方法,特别是在身体上无法进行常规口腔卫生的脆弱患者中。
公共卫生相关性:在本申请中,我们建议使用非病毒基因治疗方法来解决慢性牙周炎和口腔植物群的子集的组织破坏的公共卫生问题。具体而言,我们提出了一种抑制生物膜形成的方法,生物膜形成是一种自然过程,在最容易受到无法保持日常口腔卫生(即刷牙)的牙科患者中加速。这项技术在公共卫生领域的直接应用是提供一种基于基因治疗的治疗方法,可以为脆弱的患者提供间歇性牙周治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael J. Passineau其他文献
Michael J. Passineau的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael J. Passineau', 18)}}的其他基金
Ultrasound-Assisted AQP1 Gene Therapy for Functional Restoration of Salivary Glan
超声辅助 AQP1 基因治疗唾液腺功能恢复
- 批准号:
8390748 - 财政年份:2012
- 资助金额:
$ 11.39万 - 项目类别:
Ultrasound-Assisted AQP1 Gene Therapy for Functional Restoration of Salivary Glan
超声辅助 AQP1 基因治疗唾液腺功能恢复
- 批准号:
8514570 - 财政年份:2012
- 资助金额:
$ 11.39万 - 项目类别:
Ultrasound-Assisted AQP1 Gene Therapy for Functional Restoration of Salivary Glan
超声辅助 AQP1 基因治疗唾液腺功能恢复
- 批准号:
8668774 - 财政年份:2012
- 资助金额:
$ 11.39万 - 项目类别:
Ultrasound-Assisted AQP1 Gene Therapy for Functional Restoration of Salivary Glan
超声辅助 AQP1 基因治疗唾液腺功能恢复
- 批准号:
8878038 - 财政年份:2012
- 资助金额:
$ 11.39万 - 项目类别:
Ultrasound-Assisted Gene Transfer of Anti-Biofilm Peptides to the Salivary Gland
超声辅助将抗生物膜肽基因转移至唾液腺
- 批准号:
8225139 - 财政年份:2011
- 资助金额:
$ 11.39万 - 项目类别:
Salivary Gland-Based Gene Therapy for Lysosomal Storage Diseases
基于唾液腺的溶酶体贮积病基因治疗
- 批准号:
7814758 - 财政年份:2009
- 资助金额:
$ 11.39万 - 项目类别:
Salivary Gland-Based Gene Therapy for Lysosomal Storage Diseases
基于唾液腺的溶酶体贮积病基因治疗
- 批准号:
7848134 - 财政年份:2008
- 资助金额:
$ 11.39万 - 项目类别:
Salivary Gland-Based Gene Therapy for Lysosomal Storage Diseases
基于唾液腺的溶酶体贮积病基因治疗
- 批准号:
7623847 - 财政年份:2008
- 资助金额:
$ 11.39万 - 项目类别:
Salivary Gland-Based Gene Therapy for Lysosomal Storage Diseases
基于唾液腺的溶酶体贮积病基因治疗
- 批准号:
7616605 - 财政年份:2008
- 资助金额:
$ 11.39万 - 项目类别:
Salivary gland-based gene therapy for lysosomal storage diseases
基于唾液腺的溶酶体贮积病基因治疗
- 批准号:
7244947 - 财政年份:2007
- 资助金额:
$ 11.39万 - 项目类别:
相似海外基金
Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
- 批准号:
23K08213 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
- 批准号:
2881726 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
- 批准号:
10722146 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
- 批准号:
10935776 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
- 批准号:
10935796 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
- 批准号:
10935775 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
- 批准号:
10649041 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
- 批准号:
10735964 - 财政年份:2023
- 资助金额:
$ 11.39万 - 项目类别: